GlaxoSmithKline plc
Notice of Annual General Meeting

Thursday 5 May 2016
at 2.30pm

This document is important and requires your immediate attention. If you are in any doubt as to what action you should take, you should consult your stockbroker, bank manager, solicitor, accountant or other independent professional adviser immediately. If you have sold or otherwise transferred all of your shares, please pass this document, together with the accompanying documents, to the purchaser or transferee, or to the person who arranged the sale or transfer so they can pass these documents to the person who now holds the shares.
30 March 2016
To the holders of the company’s Ordinary Shares and American Depositary Shares.

Dear Shareholder,

Annual General Meeting 2016

I am pleased to enclose the Notice of Meeting for the sixteenth Annual General Meeting (AGM) of GlaxoSmithKline plc. The AGM will be held on Thursday 5 May 2016 at 2.30pm at The Queen Elizabeth II Conference Centre, Broad Sanctuary, Westminster, London SW1P 3EE.

If you will not be attending, you may appoint a proxy by completing and returning the enclosed proxy form. Alternatively, you may appoint a proxy electronically via www.shareview.co.uk, www.sharevote.co.uk or, if you hold your shares in CREST, via the CREST system. Notice of your appointment of a proxy should reach the company’s registrar, Equiniti, by 2.30pm on Tuesday 3 May 2016. If you hold your shares through a nominee service, please contact the nominee service provider regarding the process for appointing a proxy.

A resolution to receive and adopt the Directors’ Report and the Financial Statements for 2015 is included in the ordinary business of the AGM.

Resolutions are also proposed for the formal election of Vindi Banga and Dr Jesse Goodman as Non-Executive Directors. They were appointed by the Board since the last AGM and their biographies are set out in the explanatory notes to this document.

In accordance with the UK Corporate Governance Code, all of the other Directors of the company will stand for re-election to the Board, with the exception of Sir Deryck Maughan, who is retiring from the Board after eleven years’ service, Dr Stephanie Burns and Dr Daniel Podolsky who are both retiring from the Board after nine years’ service, and Hans Wijers, who is retiring from the Board after three years’ service.

In addition, resolutions are proposed to retain a notice period of 14 clear days for general meetings other than an AGM, albeit that the company intends to follow the new UK Corporate Governance Code guideline to provide 14 business days’ notice, and to omit from the published copies of the company’s 2016 Annual Report the name of the individual who signs the auditors’ reports on behalf of the company’s auditors.

Explanatory notes for the business of the AGM are given on pages 10 to 14 of this document.

Recommendation

Your Board believes that the resolutions contained in the Notice of Meeting are in the best interests of the company and shareholders as a whole and recommends that you vote in favour of them, as your Directors intend to do in respect of their beneficial shareholdings.

Yours sincerely,

Philip Hampton
Chairman
GlaxoSmithKline plc
Notice of Meeting

Notice is hereby given that the sixteenth AGM of GlaxoSmithKline plc will be held at The Queen Elizabeth II Conference Centre, Broad Sanctuary, Westminster, London SW1P 3EE on Thursday 5 May 2016 at 2.30pm to consider and, if thought fit, pass the following resolutions.

All resolutions will be proposed as ordinary resolutions, save for resolutions 18, 19 and 21 which will be proposed as special resolutions.

Ordinary Business

1. To receive and adopt the Directors’ Report and the Financial Statements for the year ended 31 December 2015, together with the report of the auditors.
2. To approve the Annual Report on Remuneration for the year ended 31 December 2015.
3. To elect Vindi Banga as a Director.
4. To elect Dr Jesse Goodman as a Director.
5. To re-elect Sir Philip Hampton as a Director.
6. To re-elect Sir Andrew Witty as a Director.
7. To re-elect Professor Sir Roy Anderson as a Director.
8. To re-elect Stacey Cartwright as a Director.
9. To re-elect Simon Dingemans as a Director.
10. To re-elect Lynn Elsenhans as a Director.
11. To re-elect Judy Lewent as a Director.
12. To re-elect Urs Rohner as a Director.
13. To re-elect Dr Moncef Slaoui as a Director.
14. To authorise the Audit & Risk Committee to re-appoint PricewaterhouseCoopers LLP as the auditors to the company to hold office from the end of the meeting to the end of the next meeting at which accounts are laid before the company.
15. To authorise the Audit & Risk Committee to determine the remuneration of the auditors.

Special Business

16. Donations to political organisations and political expenditure (ordinary resolution)

THAT, in accordance with sections 366 and 367 of the Companies Act 2006 (the Act) the company is, and all companies that are, at any time during the period for which this resolution has effect, subsidiaries of the company as defined in the Act, are authorised in aggregate to:

(a) make political donations, as defined in section 364 of the Act, to political parties and/or independent electoral candidates, as defined in section 363 of the Act, not exceeding £50,000 in total;

(b) make political donations to political organisations other than political parties, as defined in section 363 of the Act, not exceeding £50,000 in total; and
(c) incur political expenditure, as defined in section 365 of the Act, not exceeding £50,000 in total,
in each case during the period beginning with the date of passing this resolution and ending at the end of the next AGM of the company to be held in 2017 or, if earlier, at the close of business on 30 June 2017. In any event, the aggregate amount of political donations and political expenditure made or incurred under this authority shall not exceed £100,000.

17 Authority to allot shares (ordinary resolution)
THAT the Directors be and are hereby generally and unconditionally authorised, in accordance with section 551 of the Act, in substitution for all subsisting authorities, to exercise all powers of the company to allot shares in the company and to grant rights to subscribe for or convert any security into shares in the company up to an aggregate nominal amount of £405,824,293 which authority shall expire at the end of the next AGM of the company to be held in 2017 or, if earlier, at the close of business on 30 June 2017 (unless previously revoked or varied by the company in general meeting) save that under such authority the company may, before such expiry, make an offer or agreement which would or might require shares to be allotted or rights to subscribe for or convert any security into shares to be granted after such expiry and the Directors may allot shares or grant rights to subscribe for or convert any security into shares in pursuance of such an offer or agreement as if the relevant authority conferred hereby had not expired.

18 Disapplication of pre-emption rights (special resolution)
THAT subject to resolution 17 being passed, in substitution for all subsisting authorities, the Directors be and are hereby empowered to allot equity securities (as defined in the Act) for cash pursuant to the authority conferred on the Directors by resolution 18 and/or where such allotment constitutes an allotment of equity securities under section 560(3) of the Act, free of the restrictions in section 561(1) of the Act, provided that this power shall be limited to:

(a) the allotment of equity securities in connection with an offer or issue of equity securities to:

(i) Ordinary shareholders in proportion (as nearly as may be practicable) to their existing holdings; and

(ii) holders of other equity securities, as required by the rights of those securities or as the Board otherwise considers necessary,

but so that the Directors may impose any limits or make such exclusions or other arrangements as they consider expedient in relation to Treasury shares, fractional entitlements, record dates, legal, regulatory or practical problems under the laws of, or the requirements of, any relevant regulatory body or stock exchange, in any territory, or any matter whatsoever; and

(b) the allotment (otherwise than pursuant to sub-paragraph (a) above) of equity securities up to an aggregate nominal amount of £121,759,464, and shall expire at the end of the next AGM of the company to be held in 2017 or, if earlier, at the close of business on 30 June 2017, save that the company may, before such expiry, make an offer or agreement which would or might require equity securities to be allotted after such expiry and the Directors may allot equity securities in pursuance of such an offer or agreement as if the relevant authority conferred hereby had not expired.
19 Purchase of own shares by the company (special resolution)

THAT the company be and is hereby generally and unconditionally authorised for the purposes of section 701 of the Act to make market purchases (within the meaning of section 693(4) of the Act) of its own Ordinary Shares of 25 pence each provided that the:

(a) maximum number of Ordinary Shares hereby authorised to be purchased is 487,037,856;
(b) minimum price, exclusive of expenses, which may be paid for each Ordinary Share is 25 pence;
(c) maximum price, exclusive of expenses, which may be paid for each Ordinary Share shall be the higher of (i) an amount equal to 5% above the average market value for the company's Ordinary Shares for the five business days immediately preceding the day on which the Ordinary Share is contracted to be purchased; and (ii) the higher of the price of the last independent trade and the highest current independent bid on the London Stock Exchange Official List at the time the purchase is carried out; and
(d) authority conferred by this resolution shall, unless renewed prior to such time, expire at the end of the next AGM of the company to be held in 2017 or, if earlier, at the close of business on 30 June 2017, save that the company may, before such expiry, enter into a contract for the purchase of Ordinary Shares which would or might be completed wholly or partly after such expiry and the company may purchase Ordinary Shares pursuant to any such contract as if this authority had not expired.

20 Exemption from statement of the name of the senior statutory auditor in published copies of the auditors' reports (ordinary resolution)

THAT:

(a) in accordance with section 506 of the Act, the name of the person who signs the auditors' reports to the company's members on the annual accounts and auditable reports of the company for the year ending 31 December 2016 as senior statutory auditor (as defined in section 504 of the Act) for and on behalf of the company's auditors, should not be stated in published copies of the reports (such publication being as defined in section 505 of the Act) and the copy of the reports to be delivered to the Registrar of Companies under Chapter 10 of Part 15 of the Act; and
(b) the company considers on reasonable grounds that statement of the name of the senior statutory auditor would create or be likely to create a serious risk that the senior statutory auditor, or any other person, would be subject to violence or intimidation.

21 Reduced notice of a general meeting other than an AGM (special resolution)

THAT a general meeting of the company other than an AGM may be called on not less than 14 working days' notice.

By Order of the Board

Victoria Whyte
Company Secretary
30 March 2016
Notes

(i) All resolutions at the AGM will be decided by poll as required by the company’s Articles of Association.

(ii) A member (shareholder) of the company is entitled to appoint one or more proxies to attend the AGM, and to speak and vote on his or her behalf, provided that each proxy is appointed to exercise the rights attached to a different share or shares held by that member. A proxy need not be a member of the company.

(iii) (a) To appoint a proxy you may:

- complete the proxy form enclosed with this Notice of AGM which should be returned directly to Equiniti at the address given in Note (iii) (e); or

- if you have a Shareview portfolio, register your vote electronically by visiting www.shareview.co.uk, logging into your account and following the instructions provided; or

- register the appointment of your proxy electronically using the internet by logging on to www.sharevote.co.uk using the Voting ID, Task ID and Shareholder reference number printed on your enclosed proxy form and following the instructions provided. Please note that any electronic communication sent to the company’s registrar in respect of the appointment of a proxy that is found to contain a computer virus will not be accepted; or

- if you hold your shares in uncertificated form in CREST, you may utilise the CREST electronic proxy appointment service by using the procedures described in the CREST Manual. CREST Personal Members or other CREST Sponsored Members, and those CREST members who have appointed a service provider or providers, should refer to their CREST sponsor or voting service provider(s), who will be able to take the appropriate action on their behalf. Further details of voting via CREST are also given on page 17.

(b) The proxy appointment must be received by the company’s registrar, Equiniti, by 2.30pm on Tuesday 3 May 2016.

(c) The “Vote withheld” option is provided to enable a member to withhold his or her vote on any particular resolution. It should be noted that a vote withheld is not a vote in law and will not be counted in the calculation of the proportion of votes “For” or “Against” a resolution.

(d) If you do not have a proxy form and believe that you should have been sent one, or if you require additional proxy forms, please contact Equiniti on one of the numbers given in Note (iii) (e).

(e) The return of a completed proxy form, other instrument or any CREST Proxy Instruction will not prevent a member from attending the AGM and voting in person if he or she wishes to do so.

Equiniti can be contacted by post at:

Equiniti Limited
Aspect House
Spencer Road
Lancing, BN99 6DA
Tel: 0371 384 2991 (in the UK)*
Tel: + 44 (0)121 415 7067 (outside the UK)

* Lines are open from 8.30am to 5.30pm, UK time, Monday to Friday excluding public holidays in England and Wales.
(iv) Holders of the company's American Depositary Shares evidenced by American Depositary Receipts (ADRs) may exercise their votes through the Depositary, BNY Mellon. Such holders wishing to attend the AGM should obtain prior authority by being nominated an "Appointed Proxy" by the Depositary, who can be contacted at:

BNY Mellon Shareowner Services
PO Box 30170
College Station, TX 77842-3170

Overnight correspondence should be sent to:
BNY Mellon Shareowner Services
211 Quality Circle, Suite 210
College Station, TX 77845

www.mybnymdr.com
Tel:  +1 877 353 1154 (US toll free)
Tel:  +1 201 680 6825 (outside the US)

(v) Participants in the company's Corporate Sponsored Nominee service may exercise their votes through the company's registrar, Equiniti, by using the form of direction enclosed with this Notice of Meeting, which should be returned direct to Equiniti at the address in Note (iii) (e) above. Please note that the form of direction must be received by 5.00pm on Friday 29 April 2016.

(vi) Any person to whom this Notice is sent who is a person nominated under section 146 of the Act to enjoy information rights (a Nominated Person) may, under an agreement between him or her and the member by whom he or she was nominated, have a right to be appointed (or to have someone else appointed) as a proxy for the AGM. If a Nominated Person has no such proxy appointment right or does not wish to exercise it, he or she may, under any such agreement, have a right to give instructions to the member to exercise the voting rights.

The statements of the rights of members in relation to the appointment of proxies in Notes (ii) and (iii) above do not apply to Nominated Persons. The rights described in those Notes can only be exercised by members of the company.

(vii) Copies of service contracts or, where applicable, letters of appointment between Directors and the company or any of its subsidiaries (and any side letters relating to severance terms and pension arrangements) are available for inspection at the company's registered office given above during normal UK business hours (Saturdays, Sundays and public holidays excepted) and at the place of the AGM on Thursday 5 May 2016 from 1.00pm until the end of the meeting.

(viii) Members must be entered on the company's register of members at 6.00pm on Tuesday 3 May 2016, or, in the event of an adjournment, 6.00pm on the date which is two business days before the time of the adjourned meeting, to be entitled to attend and vote at the AGM. Members may cast votes only in respect of shares of which they were registered holders at such time, and changes to the register of members after the relevant deadline shall be disregarded in determining the rights of any person to attend and vote at the AGM.

(ix) Any corporation which is a member can appoint one or more corporate representatives who may exercise on its behalf all of its powers as a member provided that, if there is more than one corporate representative, they do not do so in relation to the same shares.
(x) Under section 527 of the Act, members meeting the threshold requirements set out in that section have the right to require the company to publish on a website a statement setting out any matter relating to: (i) the audit of the company's accounts (including the auditors' report and the conduct of the audit) that are to be laid before the AGM; or (ii) any circumstances connected with the auditors of the company ceasing to hold office since the previous meeting at which annual accounts and reports were laid in accordance with section 437 of the Act. The company may not require the shareholders requesting any such website publication to pay its expenses in complying with sections 527 or 528 of the Act. Where the company is required to place a statement on a website under section 527 of the Act, it must forward the statement to the company's auditors no later than the time when it makes the statement available on the website. The business which may be dealt with at the AGM includes any statement that the company has been required under section 527 of the Act to publish on a website.

(xi) Any shareholder, proxy or joint shareholder attending the AGM has the right to ask questions. The company must cause to be answered any such question relating to the business being dealt with at the AGM but no such answer need be given if: (i) to do so would interfere unduly with the preparation for the AGM or involve the disclosure of confidential information; (ii) the answer has already been given on a website in the form of an answer to a question; or (iii) it is undesirable in the interests of the company or the good order of the AGM that the question be answered.

(xii) In the case of joint shareholders where one or more of the joint shareholders purports to appoint a proxy, only the vote of the first named in the register of members of those who have purported to appoint a proxy shall be accepted.

(xiii) A copy of this Notice, and other information required by section 311A of the Act, can be found at www.gsk.com.

(xiv) Under sections 338 and 338A of the Act, members meeting the threshold requirements in those sections have the right to require the company: (i) to give, to members of the company entitled to receive notice of the AGM, notice of a resolution which may properly be moved and is intended to be moved at that meeting, and/or (ii) to include in the business to be dealt with at that meeting any matter (other than a proposed resolution) which may be properly included in the business. A resolution may properly be moved or a matter may properly be included in the business unless: (a) (in the case of a resolution only) it would, if passed, be ineffective (whether by reason of inconsistency with any enactment or the company's constitution or otherwise), (b) it is defamatory of any person, or (c) it is frivolous or vexatious. Such a request may be in hard copy form or in electronic form, must identify the resolution of which notice is to be given or the matter to be included in the business, must be authenticated by the person or persons making it, must have been received by the company no later than Wednesday 23 March 2016, being the date six clear weeks before the AGM, and (in the case of a matter to be included in the business only) must be accompanied by a statement setting out the grounds for the request.

(xv) Any electronic address provided either in this Notice or any related documents (including the Chairman's letter and proxy form) may not be used to communicate with the company for any purposes other than those expressly stated.

(xvi) To be admitted to the AGM, shareholders are asked to present their attendance card (which is attached to the proxy form) or present proof of identity.

(xvii) On arrival at the place of the AGM, all those entitled to vote will be required to register and collect a poll card.
Ordinary Business

Each of these resolutions will be proposed as an ordinary resolution. This means that for each of the resolutions to be passed, more than half of the votes cast must be in favour of the resolution.

Resolution 1 – To receive and adopt the Directors’ Report and the Financial Statements for 2015

For each financial year, the Directors must present the Directors’ Report, the audited Financial Statements and the independent auditors’ reports to shareholders at a general meeting.

Resolution 2 – To approve the Annual Report on Remuneration

In accordance with section 439 of the Companies Act 2006, resolution 2 seeks shareholder approval for the Annual Report on Remuneration (the “Report”) which gives details of the implementation of the company’s Remuneration Policy (the “Policy”). The Report gives details of the payments and share awards made to directors in connection with their performance and that of the company during the year ended 31 December 2015, and can be found in the Annual Report. The Report is prepared annually and is subject to an advisory shareholder vote, and the Directors’ entitlement to remuneration is not conditional on this resolution being passed.

The Policy which sets out the company’s policy on directors’ remuneration, including the setting of directors’ pay and the granting of share awards can be found on pages 117 to 126 of the 2013 Annual Report and at www.gsk.com in the Investors section. The company presented the Policy to shareholders for approval, by a vote which was binding on the company, at the 2014 AGM. Over 97% of the votes cast on the resolution were in favour of the Policy and that approval remains effective for a period of three years from the 2014 AGM. The company is only able to make payments within the limits the Policy allows, until such time that an amended policy is approved by shareholders. A summary of the Policy has been included in the Annual Report. The company’s auditors, PricewaterhouseCoopers LLP, have audited those parts of the Report required to be audited and their report may be found in the Annual Report.

Resolutions 3-13 – To elect and re-elect Directors

The company’s Articles of Association require any Director newly appointed to the Board to retire at the first AGM after their appointment. The Board recommends that you elect as Non-Executive Directors, Vindi Banga who was appointed to the Board on 1 September 2015 and Dr Jesse Goodman who was appointed to the Board on 1 January 2016. The Board has determined that Mr Banga and Dr Goodman are independent Non-Executive Directors in accordance with the UK Corporate Governance Code.

Mr Banga, 61, worked for Unilever plc from 1977 to 2010 in a number of senior positions. In his last role at Unilever, he was President of the Global Foods, Home & Personal Care businesses, as well as being a member of the Unilever Executive Board. He is currently a partner at the private equity fund Clayton Dubilier & Rice and Chairman of the Supervisory Board of Mauser Group. He is also Senior Independent Director of Marks & Spencer Group plc and a Non-Executive Director at Thomson Reuters Corporation.

The Board considers that Mr Banga brings with him many years of experience and a track record of delivering outstanding performance in a highly competitive global consumer-focused industry which will be invaluable to GSK.

Dr Goodman, 64, is currently Professor of Medicine at Georgetown University, and previously served in senior leadership positions at the US Food and Drug Administration (‘FDA’), including most recently as FDA’s chief scientist and previously as Director of the Center for Biologics Evaluation and Research. Dr Goodman directs the Georgetown University Center on Medical Products Access, Safety and Stewardship (COMPASS) and is an active clinician who serves as Attending Physician in Infectious Diseases.
The Board considers that Dr Goodman, a leader in public health who brings a wealth of expertise spanning science, medicine, vaccines, regulation and public health, will bring crucial medical and scientific expertise to GSK, given his proven track record in addressing public health needs from both the academic and federal sectors.

In accordance with the UK Corporate Governance Code, all of the other Directors will stand for re-election to the Board, with the exception of Sir Deryck Maughan, who is retiring from the Board after eleven years' service, Dr Stephanie Burns and Dr Daniel Podolsky who are both retiring from the Board after nine years' service, and Hans Wijers, who is retiring from the Board after three years' service.

Date of original election at AGM

<table>
<thead>
<tr>
<th>Name</th>
<th>Year</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dr Moncef Slaoui</td>
<td>2006</td>
</tr>
<tr>
<td>Professor Sir Roy Anderson &amp; Sir Andrew Witty</td>
<td>2008</td>
</tr>
<tr>
<td>Stacey Cartwright, Simon Dingemans &amp; Judy Lewent</td>
<td>2011</td>
</tr>
<tr>
<td>Lynn Elsenhans</td>
<td>2013</td>
</tr>
<tr>
<td>Sir Philip Hampton &amp; Urs Rohner</td>
<td>2015</td>
</tr>
</tbody>
</table>

Following a formal evaluation process, the Chairman is satisfied that each of the Directors standing for re-election continues to perform effectively and demonstrates commitment to his or her role, including commitment of time to Board and Committee meetings and his or her other duties.

Professor Sir Roy Anderson has served as a Non-Executive Director for more than six years and his performance has been subject to a rigorous review. The Board has concluded that he continues to be effective as a Non-Executive Director.

Led by the Senior Independent Director and the SID Designate, the Non-Executive Directors met without the Chairman present to consider the Chairman's performance. The Senior Independent Director and other Non-Executive Directors are satisfied that the Chairman is performing effectively and demonstrates commitment to his role, including commitment of time to Board and Committee meetings and his other duties.

All the Non-Executive Directors have letters of appointment rather than service contracts. Sir Andrew Witty, Simon Dingemans and Dr Moncef Slaoui have service contracts with notice periods of 12 months. The Non-Executive Directors' letters of appointment and Executive Directors' service contracts are available for inspection as specified in Note (vii).

Biographical details of all the Directors are given in the company's Annual Report and on www.gsk.com.

Resolutions 14 and 15 – To authorise the Audit & Risk Committee to re-appoint PricewaterhouseCoopers LLP as auditors to the company and to determine their remuneration

At every general meeting at which accounts are presented to shareholders, the company is required to appoint auditors to serve from the end of the meeting until the next such meeting. PricewaterhouseCoopers LLP (PwC) have indicated that they are willing to continue as the company's auditors for a further year. The Audit & Risk Committee has reviewed PwC’s effectiveness and the effectiveness of their audit process and recommends their re-appointment. You are asked to authorise the Audit & Risk Committee to re-appoint them and, following normal practice, to authorise the Audit & Risk Committee to determine their remuneration. Details of the company’s policy with regard to the appointment of auditors, tendering the audit contract, the allocation of non-audit work and details of work undertaken by the auditors and their remuneration are given in our Annual Report, which can be viewed on www.gsk.com.
**Special Business**

For a resolution proposed as a special resolution to be passed, at least three-quarters of the votes cast must be in favour of the resolution.

**Resolution 16 – Donations to political organisations and political expenditure (ordinary resolution)**

With effect from 1 January 2009, to ensure a consistent approach to political contributions across the GlaxoSmithKline group, the company introduced a global policy to voluntarily stop making political donations.

The Act requires companies to obtain shareholder approval before they can make donations to EU political parties, other political organisations or independent election candidates, or incur EU political expenditure. The company does not make and does not intend to make donations to political parties, other political organisations or independent election candidates, nor does it incur, or intend to incur, EU political expenditure, within the ordinary meaning of those words. However, the definitions of political donations, political expenditure and political organisations used in the Act are very wide. In particular, the definition of political organisations may extend to bodies such as those concerned with the environment, which the company and its subsidiaries might wish to support. As a result, the definitions may cover legitimate business activities not in the ordinary sense considered to be political donations or political expenditure. Such activities are not designed to support any political party or independent election candidate or to influence public support for any political party or independent election candidate. The authority which the Board is requesting is a precautionary measure to ensure that the company and its subsidiaries do not inadvertently breach the Act, and will be capped at £100,000 for the next year.

No payments have been made under previous authorities given in this regard.

**Resolution 17 – Authority to allot shares (ordinary resolution)**

This resolution gives the Directors authority to allot unissued share capital with a nominal value of up to £405,824,293 (representing 1,623,297,172 Ordinary Shares of 25 pence each) which, as at 1 March 2016, being the latest practicable date prior to the publication of this Notice, represented 33.33% of the issued share capital of the company (excluding Treasury shares).

The authority sought under this resolution will expire on the earlier of close of business on 30 June 2017 (being the last date by which the company must hold an AGM in 2017) and the conclusion of the AGM to be held by the company in 2017.

The Directors have no present intention to exercise the authority sought under this resolution, except to fulfil the company’s obligations under its executive and employee share plans.

**Resolution 18 – Disapplication of pre-emption rights (special resolution)**

This resolution gives the Directors authority to allot Ordinary Shares (including any Ordinary Shares which the company has purchased and elected to hold as Treasury shares) for cash without first offering them to existing shareholders in proportion to their existing shareholdings and is limited to allotments or sales in connection with rights issues or other pre-emptive offers, or otherwise up to a maximum nominal amount of £121,759,464 (representing 487,037,856 Ordinary Shares of 25 pence each), which, as at 1 March 2016, being the latest practicable date prior to the publication of this Notice, represented just less than 10% of the company’s issued share capital (excluding Treasury shares).
This authority is in line with the Pre-emption Groups’ Statement of Principles (the ‘Pre-emption Principles’), which were revised in March 2015 to allow the authority for a non-pre-emptive issue of shares for cash to be increased from 5% to 10% of the company’s issued ordinary share capital, provided that the company confirms that it intends to use the additional 5% only in connection with an acquisition or specified capital investment.

The Board therefore confirms, in accordance with the Pre-emption Principles, that to the extent that the authority in resolution 17 (that is the authority to allot equity securities with a nominal amount of up to £405,824,293) is used for a non-pre-emptive issue of ordinary shares with a nominal value in excess of £60,879,732 (that is 5% of the company’s issued ordinary share capital (excluding Treasury shares) as at 1 March 2016), it intends that it will only be used in connection with an acquisition or specified capital investment which is announced contemporaneously with the issue, or which has taken place in the preceding six month period and is disclosed in the announcement of the issue.

In respect of this aggregate nominal amount, the Directors confirm their intention to follow the provisions of the Pre-emption Principles regarding cumulative usage of authorities within a rolling three-year period, where the Principles provide that usage in excess of 7.5% should not take place, save as permitted in connection with an acquisition or specified capital investment, without prior consultation with shareholders.

The authority sought under this resolution will expire on the earlier of close of business on 30 June 2017 (being the last date by which the company must hold an AGM in 2017) and the conclusion of the AGM to be held by the company in 2017. This authority is granted under sections 570 and 573 of the Act and is a standard authority taken by most listed companies each year.

The company’s current intention is to satisfy the exercise of outstanding options by the issue of new Ordinary Shares or by using Ordinary Shares held in Treasury.

**Resolution 19 – Purchase of own shares by the company (special resolution)**

This resolution seeks authority for the company to make market purchases of its own Ordinary Shares. In certain circumstances it may be advantageous for the company to purchase its own shares and the Directors consider it to be desirable for this general authority to be available to provide flexibility in the management of the company’s capital resources. Purchases of the company’s own shares will be made only if to do so would result in an increase in earnings per share and would be in the best interests of shareholders generally. You are asked to consent to the purchase by the company of up to a maximum of 487,037,856 Ordinary Shares, which, as at 1 March 2016, being the latest practicable date prior to the publication of this Notice, represented just less than 10% of the company’s issued share capital (excluding Treasury shares). The authority sought under this resolution will expire on the earlier of close of business on 30 June 2017 (being the last date by which the company must hold an AGM in 2017) and the conclusion of the AGM to be held by the company in 2017. The maximum price which may be paid for an Ordinary Share will be the higher of (i) 105% of the average middle market quotations for the five business days preceding the purchase and (ii) the higher of the price of the last independent trade and the highest current independent bid at the time the purchase is carried out. The minimum price which may be paid for an Ordinary Share is its nominal value of 25 pence. The company may either retain any of its own shares which it has purchased as Treasury shares with a view to possible re-issue at a future date, use them to satisfy awards under employee share plans or cancel them. Holding the shares as Treasury shares gives management the ability to re-issue them quickly and cost-effectively and would provide the company with additional flexibility in the management of its capital base.
In any event the company confirms that it does not currently intend to make any further market purchases in 2016. This authority is being sought to preserve flexibility to do so should there be a change in circumstances. The company will review the potential for future share buy backs during 2017 in line with its usual annual cycle and subject to its current return and ratings criteria.

The total number of options over Ordinary Shares outstanding as at 1 March 2016, being the latest practicable date prior to the publication of this Notice, was approximately 36 million, representing approximately 0.73% of the issued share capital (excluding Treasury shares). If the authority to buy back shares under this resolution was exercised in full, the total number of options to subscribe for Ordinary Shares outstanding as at 1 March 2016 would, assuming no further Ordinary Shares are issued, represent approximately 0.81% of the issued share capital (excluding Treasury shares).

Resolution 20 – Exemption from statement of the name of the senior statutory auditor in published copies of the auditors’ reports (ordinary resolution)

The Act requires that each and every copy of the auditors’ reports to the company’s shareholders on the Annual Report, and other auditable reports, which are published by or on behalf of the company, must state, where the company’s auditors are a firm, the name of the person who signed them in his or her own name as senior statutory auditor in relation to the audit, for and on behalf of the auditors. However, the Act provides an exemption from this requirement if the company considers on reasonable grounds that statement of the individual’s name would create, or be likely to create, a serious risk that he or she or any other person would be subject to violence or intimidation.

For many years, the company and its legacy companies, together with its employees, have been the focus of protests by various animal protection groups, some of which have engaged in aggressive, abusive and hostile acts. The Directors therefore believe that it is appropriate that the company should seek to utilise the confidentiality afforded to the senior statutory auditor of the company’s auditors under the Act. This resolution therefore seeks shareholder approval for the auditors’ reports for the financial year ending 31 December 2016 to omit the name of the senior statutory auditor. The company would give notice to the Secretary of State in the appropriate format if this resolution is passed.

Resolution 21 – Reduced notice of a general meeting other than an AGM (special resolution)

This resolution seeks to renew an authority granted at last year’s AGM to allow the company to call general meetings other than an AGM on 14 clear days’ notice. Changes made to the Act by The Companies (Shareholders’ Rights) Regulations 2009 (the Shareholders’ Rights Regulations) increase the notice period required for general meetings of the company to 21 days unless shareholders approve a shorter notice period, which cannot be less than 14 clear days. AGMs will continue to be held on at least 21 clear days’ notice.

Before the Shareholders’ Rights Regulations came into force on 3 August 2009, the company was able to call general meetings other than an AGM on 14 clear days’ notice without obtaining such shareholder approval. Resolution 21 seeks to preserve this ability. If passed, this resolution will enable the company to retain maximum flexibility to seek shareholder approval for any future changes or transactions that may require such approval. The resolution will be effective until the company’s next AGM, when it is intended that a similar resolution will be proposed.

The company confirms that it will give as much notice as practicable, and in particular that it will endeavour to comply with the UK Corporate Governance Code by giving at least 14 working days’ notice when calling a general meeting. The company envisages that this authority would only be used in circumstances where a shorter notice period would in the Board’s opinion be to the advantage of shareholders as a whole, and where flexibility is merited by the nature of the business of the meeting. Shareholders should note that if the company calls a general meeting on less than 21 clear days’ notice, the company will provide a means for all shareholders to vote electronically for that meeting.
Additional information

Issued share capital
All references to the company's "issued share capital" in the Explanatory Notes are to the company's issued share capital as at 1 March 2016, which was 4,870,378,563 Ordinary Shares, excluding any Ordinary Shares held as Treasury shares. As at 1 March 2016, the company held 491,515,950 Ordinary Shares as Treasury shares, representing 10.09% of the company's issued share capital (excluding Treasury shares) as at that date. As at 1 March 2016, the total number of voting rights in the company was 4,870,378,563.

The following information is provided in respect of Part 6 of Schedule 7 of the Large and Medium-sized Companies and Groups (Accounts and Reports) Regulations 2008:

Share capital and control
The company's shares are listed on the London Stock Exchange and are also quoted on the New York Stock Exchange in the form of American Depositary Shares (ADS). Each ADS represents two Ordinary Shares.

The holders of Ordinary Shares are entitled to receive dividends when declared and the company's Annual Report, to attend and speak at general meetings of the company, to appoint proxies and to exercise voting rights.

There are no restrictions on transfer, or limitations on the holding of Ordinary Shares, and no requirements to obtain prior approval to any transfers. No Ordinary Shares carry any special rights with regard to control of the company and there are no restrictions on voting rights. Major shareholders have the same voting rights per share as all other shareholders. There are no known arrangements under which financial rights are held by a person other than the holder of the shares and no known agreements or restrictions on share transfers or on voting rights.

Shares acquired through GSK share schemes and plans rank equally with the other shares in issue and have no special rights. The trustees of the company's Employee Share Ownership Plan Trusts have waived their rights to dividends on shares held by the Trusts.

Change of control
The company is not party to any significant agreements that would take effect, alter or terminate upon a change of control following a takeover bid.

The company does not have agreements with any Director or Officer that would provide compensation for loss of office or employment resulting from a takeover, except that provisions of the company's share plans may cause options and awards granted under such plans to vest on a takeover.

Interests in voting rights
Details of the notifiable interests in the total voting rights in the company's issued share capital are given in the 2015 Annual Report.

Information provided to the company pursuant to the Financial Conduct Authority's Disclosure and Transparency Rules is published on a Regulatory Information Service and on the company's website.

The company has not acquired or disposed of any interests in its own shares, other than in connection with the company's share buy-back programme. Details of the shares purchased, cancelled and held in Treasury are given in the Annual Report.
Directors
The interests of Directors and their connected persons in the issued share capital of the company are given in the 2015 Annual Report.

The rules about the appointment and replacement of Directors are contained in the company's Articles of Association. The company's Articles must be approved by shareholders in accordance with the legislation in force from time to time and may be amended by a special resolution of the members.

The Articles provide that Directors may be appointed by an ordinary resolution of the members or by a resolution of the Directors, provided that, in the latter instance, a Director appointed in this way retires at the first AGM following his or her appointment.

The Articles also require that at every AGM certain of our current Directors retire by rotation and detail the circumstances in which and how they may be re-elected. However, the Board has decided that all Directors who wish to stand for re-election will retire at the AGM on 5 May 2016 in accordance with the UK Corporate Governance Code. The company's members may remove a Director by passing an ordinary resolution of which special notice has been given or by passing a special resolution.

A Director will automatically cease to be a Director if (i) he or she becomes bankrupt or compounds with his or her creditors generally, (ii) he or she is or has been suffering from mental or physical ill health and the Board resolves that his or her office is vacated, (iii) he or she has missed Directors’ meetings for a continuous period of six months without permission and the Board resolves that he or she shall cease to be a Director, (iv) he or she is prohibited from being a Director by law, (v) he or she ceases to be a Director by virtue of UK companies legislation or is removed from office pursuant to the company's Articles of Association, (vi) he or she resigns, (vii) he or she offers to resign and the Board accepts that offer, or (viii) his or her resignation is requested by all of the other Directors and all of the other Directors are not fewer than three in number.

The powers of the Directors are determined by UK legislation and the company's Articles of Association, available on www.gsk.com. As provided in those Articles, the Directors may exercise all the company’s powers provided that the Articles or applicable legislation do not stipulate that any such powers must be exercised by the members. The Directors have been authorised to issue and allot Ordinary Shares, and have authority to make market purchases of shares. Renewal of these authorities is sought from shareholders at each AGM. Any shares purchased may be cancelled or held as Treasury shares.
Information on how to vote electronically

**Voting using Shareview**
If you have a Shareview portfolio, you may register your vote electronically by visiting www.shareview.co.uk, logging into your account and following the instructions provided.

**Voting using Sharevote**
You may register your vote electronically by logging on to www.sharevote.co.uk using the Voting ID, Task ID and Shareholder reference number printed on your enclosed proxy form and following the instructions provided. If you would like to cast your vote electronically you need to do so by 2.30pm on Tuesday 3 May 2016.

**Voting using CREST’s electronic proxy appointment service**
If you hold your shares in uncertificated form in CREST you may use the electronic proxy appointment service operated by CREST to appoint a proxy or proxies and register your vote. CREST members who wish to appoint a proxy or proxies by utilising the CREST electronic proxy appointment service may do so for the AGM to be held on Thursday 5 May 2016 and any adjournment(s) thereof by utilising the procedures described in the CREST Manual (available via www.euroclear.com). CREST Personal Members or other CREST Sponsored Members, and those CREST members who have appointed a voting service provider or providers, should refer to their CREST sponsor or voting service provider(s), who will be able to take the appropriate action on their behalf.

For a proxy appointment or instruction made using the CREST service to be valid, the appropriate CREST message (a “CREST Proxy Instruction”) must be properly authenticated in accordance with Euroclear’s specifications and must contain the information required for such instructions, as described in the CREST Manual.

The message, regardless of whether it constitutes the appointment of a proxy or is an amendment to an instruction to a previously appointed proxy, must, in order to be valid, be transmitted so as to be received by the issuer’s agent, Equiniti ID RA19 by 2.30pm on Tuesday 3 May 2016.

For this purpose, the time of receipt will be taken to be the time (as determined by the timestamp applied to the message by the CREST Applications Host) from which the issuer’s agent is able to retrieve the message by enquiry to CREST in the manner prescribed by CREST. After this time any change of instructions to proxies appointed through CREST should be communicated to the appointee through other means.

CREST members and, where applicable, their CREST sponsors or voting service providers should note that Euroclear does not make available special procedures in CREST for any particular messages. Normal system timings and limitations will therefore apply in relation to the input of CREST Proxy Instructions.

It is the responsibility of the CREST member concerned to take (or, if the CREST member is a CREST Personal Member or Sponsored Member or has appointed a voting service provider or providers, to procure that his CREST sponsor or voting service provider(s) take(s)) such action as shall be necessary to ensure that a message is transmitted by means of the CREST system by any particular time. In this connection, CREST members and, where applicable, their CREST sponsors or voting service providers are referred, in particular, to those sections of the CREST Manual concerning practical limitations of the CREST system and timings.

The company may treat as invalid a CREST Proxy Instruction in the circumstances set out in Regulation 35(5)(a) of the Uncertificated Securities Regulations 2001.